Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment
Sponsor: Kasr El Aini Hospital
Summary
This is a randomized, double-blind, controlled clinical trial investigating the efficacy and safety of millet seed extract capsules in treating telogen effluvium in female patients. The study will recruit 60 female participants with telogen effluvium who will be randomly assigned to receive either millet seed extract capsules (containing 420 mg millet seed extract, 200 mcg biotin, 6 mg L-cystine, and 27.48 mg vitamin B5) twice daily or Biotin forte capsules (5 mg biotin) once daily for 12 weeks. The primary outcome will measure changes in telogen and anagen hair densities using dermoscopy-assisted phototrichography. Secondary outcomes will assess patient satisfaction and unwanted body hair growth. Safety will be monitored throughout the study period at Cairo University's dermatology clinic.
Official title: Efficacy and Safety of Millet Seed Extract in the Treatment of Telogen Effluvium in Female Patients: A Randomized, Double-Blind, Controlled Trial
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05-01
Completion Date
2026-03-01
Last Updated
2026-05-05
Healthy Volunteers
No
Conditions
Interventions
Millet Seed Extract group
Millet seed extract capsules containing 420 mg millet seed extract, 200 mcg biotin, 6 mg L-cystine, and 27.48 mg vitamin B5, taken orally twice daily for 12 weeks. The extract is standardized to miliacin content.
Biotin group
Capsules containing 5 mg of biotin, taken orally once daily for 12 weeks.
Locations (1)
Kasr El Aini Hospital
Cairo, Cairo Governorate, Egypt